Welcome to Multibagg AI
Log in to access personalized features
Dashboard
Portfolio
Ask Iris
Discovery
Timeline
Multibagg AI is an AI powered stock research and analysis platform. We provide data, information, content, and analytics for publicly traded Indian companies listed on NSE and BSE. AI can make mistakes, check important information.
Prices might be delayed by a few minutes.
Join our Exclusive Community
Join our Exclusive Community
Made with 💙 in India. © Finsky Technologies Pvt Ltd. 2026
Get instant AI-powered insights about company performance, financials, and strategy. Ask questions about trends, competition, and developments while receiving responses backed by official documents and market data, with clear attribution to source documents.
Discover detailed, AI-driven financial summaries that break down key metrics, trends, and insights—empowering you to make smarter investment decisions.
View Standalone
View Standalone
View Standalone
View Standalone
View Standalone
View Standalone
View Standalone
View Standalone
Investor Presentation
Q3 FY26
Investor Presentation
Q2 FY26
Investor Presentation
Q1 FY26
Available on Pro Plan
Unlock reports, presentations, and AI-powered insights.
Investor Presentation
Q4 FY25
Available on Pro Plan
Unlock reports, presentations, and AI-powered insights.
Investor Presentation
Q3 FY25
Available on Pro Plan
Unlock reports, presentations, and AI-powered insights.
Investor Presentation
Q2 FY25
Available on Pro Plan
Unlock reports, presentations, and AI-powered insights.
Investor Presentation
Q1 FY25
Available on Pro Plan
Unlock reports, presentations, and AI-powered insights.
Investor Presentation
Q4 FY24
Available on Pro Plan
Unlock reports, presentations, and AI-powered insights.
Bearish
2
Neutral
8
Bullish
4
Bearish
13
Neutral
8
Bullish
25
Bearish
11
Neutral
0
Bullish
21
Discovery themes featuring this stock
Apollo Hospitals Enterprise Ltd is a pan‑India integrated healthcare provider operating hospitals, diagnostics, primary care clinics, an omni‑channel pharmacy distribution network and a large digital healthcare platform, with a consolidated network that includes 76 hospitals, ~10,325 capacity beds and material subsidiaries Apollo HealthCo and AHLL delivering out‑of‑hospital care and retail diagnostics.
Q3 FY26 consolidated revenues grew 17% year‑on‑year to ₹64,774 million with EBITDA up 27% to ₹9,653 million and PAT up 35% to ₹5,023 million, driven by 14% healthcare services growth, 20% HealthCo revenue growth and AHLL diagnostics expansion; digital losses narrowed significantly and HealthCo cash profit doubled versus prior year.
Apollo is pursuing an aggressive capacity build and M&A agenda: a ~₹8,200 crore bed expansion pipeline to add ~4,444 beds over FY26–FY30, plus a composite scheme to spin and list the combined HealthCo/Keimed entity as NewCo, an initiative that reconfigures ownership and aims to unlock value through listing by Q4 FY27.
Digital and platform businesses are scaling: Apollo 24|7 reports ~46 million registered users and ~9.5 lakh daily active users, platform GMV grew ~28% in Q3 FY26, Apollo Pharmacy operates 7,113 stores, and Apollo is integrating AI, telehealth and insurance solutions to increase omni‑channel customer journeys and diagnostic/pharmacy penetration across India.
Healthcare Services
Hospital
1,10,773 Cr
Low Risk
61.5
56.4
2.0
12.2
8,099.00
6,511.05
Sales CAGR
Profit CAGR
ROE
ROCE
Apollo Hospitals Enterprise Ltd (APOLLOHOSP) is currently trading at 7,650.00 per share. Stock prices fluctuate during market hours on NSE and BSE based on demand, company updates, and overall market conditions. Refer to the live price chart above for the most recent price movement.
Apollo Hospitals Enterprise Ltd is a pan‑India integrated healthcare provider operating hospitals, diagnostics, primary care clinics, an omni‑channel pharmacy distribution network and a large digital healthcare platform, with a consolidated network that includes 76 hospitals, ~10,325 capacity beds and material subsidiaries Apollo HealthCo and AHLL delivering out‑of‑hospital care and retail diagnostics. Q3 FY26 consolidated revenues grew 17% year‑on‑year to ₹64,774 million with EBITDA up 27% to ₹9,653 million and PAT up 35% to ₹5,023 million, driven by 14% healthcare services growth, 20% HealthCo revenue growth and AHLL diagnostics expansion; digital losses narrowed significantly and HealthCo cash profit doubled versus prior year. Apollo is pursuing an aggressive capacity build and M&A agenda: a ~₹8,200 crore bed expansion pipeline to add ~4,444 beds over FY26–FY30, plus a composite scheme to spin and list the combined HealthCo/Keimed entity as NewCo, an initiative that reconfigures ownership and aims to unlock value through listing by Q4 FY27. Digital and platform businesses are scaling: Apollo 24|7 reports ~46 million registered users and ~9.5 lakh daily active users, platform GMV grew ~28% in Q3 FY26, Apollo Pharmacy operates 7,113 stores, and Apollo is integrating AI, telehealth and insurance solutions to increase omni‑channel customer journeys and diagnostic/pharmacy penetration across India.
Over the past 52 weeks, Apollo Hospitals Enterprise Ltd has traded between a low of ₹6,511.05 and a high of ₹8,099.00. The 52-week high and low indicate the stock’s price range over the last year and help investors understand its volatility and recent trading levels.
Apollo Hospitals Enterprise Ltd has a market capitalization of approximately 1,10,773.14. Market capitalization represents the total value of a company’s outstanding shares and helps investors understand its size, stability, and relative risk compared to other listed companies.
Apollo Hospitals Enterprise Ltd’s investment profile depends on its business fundamentals, valuation, and long-term outlook. The stock currently trades at a PE ratio of 61.48 and operates in the its sector sector. Investors typically assess financial performance, growth prospects, and individual risk tolerance before making investment decisions.
Based on its market capitalization of 1,10,773.14 Cr, Apollo Hospitals Enterprise Ltd is classified as a Large Cap stock. Large-cap stocks are generally more stable, while mid-cap and small-cap stocks tend to offer higher growth potential along with higher price volatility.
Apollo Hospitals Enterprise Ltd operates in the its sector sector. Sector classification matters because companies in the same sector are often affected by similar economic conditions, regulatory changes, and competitive dynamics, which can influence overall stock performance.
The Price-to-Earnings (PE) ratio of Apollo Hospitals Enterprise Ltd is 61.48. The PE ratio compares a company’s share price to its earnings and is commonly used to assess valuation. Comparing the PE ratio with sector peers and historical levels provides better context.
It is a strategic restructuring plan where Apollo Hospitals demerges its omnichannel pharmacy and digital health businesses into a new company, Apollo Healthtech Limited, which will also absorb Apollo Healthco and Keimed Private Limited.
The primary goal is to demerge its pharmacy and digital health businesses into a new, separate entity named Apollo Healthtech Limited (AHTL) and list it on the stock exchanges to unlock its value.
Master Capital Services has recommended buying Aurobindo Pharma, Apollo Hospitals Enterprise Ltd, and Coal India from a short-term trading perspective.
Citi has reiterated a 'Buy' rating on Apollo Hospitals and raised its target price to Rs 9,600 per share, suggesting a potential upside of around 33% from recent levels.
| Symbol | Watchlist | Price | Market Cap | P/E | P/B | Div Yield (%) | ROE (%) | ROCE (%) | ROA (%) |
7303.30 | 1,10,773 Cr | 61.48 | 12.19 | 0.16 | 18.39 | 16.07 | 8.50 | ||
1010.35 | 97,874 Cr | 68.96 | 9.74 | 0.15 | 13.50 | 12.81 | 8.72 | ||
915.00 | 70,558 Cr | 73.51 | 7.48 | 0.11 | 10.75 | 12.26 | 6.53 | ||
658.90 | 36,240 Cr | 110.83 | 8.66 | 0.69 | 8.18 | 10.11 | 4.60 | ||
1765.00 | 36,146 Cr | 46.41 | 8.90 | 0.25 | 20.82 | 17.75 | 10.07 | ||
1001.30 | 30,829 Cr | 59.99 | 8.32 | 0.00 | 15.15 | 16.83 | 9.50 | ||
680.00 | 26,623 Cr | 88.54 | 11.73 | 0.00 | 14.80 | 10.88 | 4.75 | ||
| Median: 7 Co. | — | 1001.30 | 36,240 Cr | 68.96 | 8.90 | 0.15 | 14.80 | 12.81 | 8.50 |
